Does the media prefer CTNM or XERS?

In the previous week, Xeris Biopharma had 13 more articles in the media than Contineum Therapeutics. MarketBeat recorded 19 mentions for Xeris Biopharma and 6 mentions for Contineum Therapeutics. Xeris Biopharma's average media sentiment score of 0.64 beat Contineum Therapeutics' score of 0.07 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 7 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CMPS or CTNM?

Contineum Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Contineum Therapeutics N/A N/A -$59.98M -$1.73 N/A

Is CMPS or CTNM more profitable?

Contineum Therapeutics' return on equity of -24.73% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Contineum Therapeutics N/A -24.73% -23.51%

Does the media refer more to CMPS or CTNM?

In the previous week, Contineum Therapeutics had 1 more articles in the media than Compass Pathways. MarketBeat recorded 6 mentions for Contineum Therapeutics and 5 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.35 beat Contineum Therapeutics' score of 0.07 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OCUL or CTNM?

In the previous week, Ocular Therapeutix had 8 more articles in the media than Contineum Therapeutics. MarketBeat recorded 14 mentions for Ocular Therapeutix and 6 mentions for Contineum Therapeutics. Ocular Therapeutix's average media sentiment score of 0.08 beat Contineum Therapeutics' score of 0.07 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANIP or CTNM?

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 6 articles in the media. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Contineum Therapeutics' score of 0.07 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, GHRS or CTNM?

GH Research is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$1.00 N/A Contineum Therapeutics N/A N/A -$59.98M -$1.73 N/A

Is GHRS or CTNM more profitable?

GH Research's return on equity of -20.86% beat Contineum Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -20.86% -20.12% Contineum Therapeutics N/A -24.73% -23.51%

Does the media favor GHRS or CTNM?

In the previous week, Contineum Therapeutics had 5 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Contineum Therapeutics' score of 0.07 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Contineum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Contineum Therapeutics (CTNM) Competitors

$13.12 +0.13 (+1.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$13.13 +0.01 (+0.08%)

As of 10/2/2026 07:30 PM Eastern

Compare

CTNM vs. XERS, CMPS, OCUL, ANIP, and GHRS

Should you buy Contineum Therapeutics stock or one of its competitors? Contineum Therapeutics's main competitors and comparable companies include Xeris Biopharma (XERS), Compass Pathways (CMPS), Ocular Therapeutix (OCUL), ANI Pharmaceuticals (ANIP), and GH Research (GHRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Contineum Therapeutics compare to Xeris Biopharma?

Contineum Therapeutics (NASDAQ:CTNM) and Xeris Biopharma (NASDAQ:XERS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Xeris Biopharma had 13 more articles in the media than Contineum Therapeutics. MarketBeat recorded 19 mentions for Xeris Biopharma and 6 mentions for Contineum Therapeutics. Xeris Biopharma's average media sentiment score of 0.64 beat Contineum Therapeutics' score of 0.07 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	7 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has higher revenue and earnings than Contineum Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.73	N/A
Xeris Biopharma	$335.41M	4.94	$550K	-$0.11	N/A

Contineum Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. 7.9% of Contineum Therapeutics shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Contineum Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Contineum Therapeutics	N/A	-24.73%	-23.51%
Xeris Biopharma	-5.12%	338.21%	3.50%

Contineum Therapeutics presently has a consensus target price of $22.17, indicating a potential upside of 68.95%. Xeris Biopharma has a consensus target price of $12.80, indicating a potential upside of 40.97%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Contineum Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Xeris Biopharma beats Contineum Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Contineum Therapeutics' return on equity of -24.73% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Contineum Therapeutics	N/A	-24.73%	-23.51%

In the previous week, Contineum Therapeutics had 1 more articles in the media than Compass Pathways. MarketBeat recorded 6 mentions for Contineum Therapeutics and 5 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.35 beat Contineum Therapeutics' score of 0.07 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Contineum Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.73	N/A

46.2% of Compass Pathways shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Compass Pathways currently has a consensus price target of $23.36, suggesting a potential upside of 96.28%. Contineum Therapeutics has a consensus price target of $22.17, suggesting a potential upside of 68.95%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Compass Pathways beats Contineum Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Ocular Therapeutix has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Contineum Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

In the previous week, Ocular Therapeutix had 8 more articles in the media than Contineum Therapeutics. MarketBeat recorded 14 mentions for Ocular Therapeutix and 6 mentions for Contineum Therapeutics. Ocular Therapeutix's average media sentiment score of 0.08 beat Contineum Therapeutics' score of 0.07 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.2% of Ocular Therapeutix shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Contineum Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Contineum Therapeutics' return on equity of -24.73% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Contineum Therapeutics	N/A	-24.73%	-23.51%

Contineum Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$52.06M	29.36	-$265.94M	-$1.42	N/A
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.73	N/A

Ocular Therapeutix currently has a consensus target price of $25.29, suggesting a potential upside of 263.30%. Contineum Therapeutics has a consensus target price of $22.17, suggesting a potential upside of 68.95%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ocular Therapeutix beats Contineum Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Contineum Therapeutics compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

ANI Pharmaceuticals has a net margin of 11.07% compared to Contineum Therapeutics' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Contineum Therapeutics	N/A	-24.73%	-23.51%

ANI Pharmaceuticals currently has a consensus target price of $98.00, suggesting a potential upside of 35.77%. Contineum Therapeutics has a consensus target price of $22.17, suggesting a potential upside of 68.95%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Contineum Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

ANI Pharmaceuticals has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37M	1.88	$78.34M	$4.64	15.56
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.73	N/A

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 6 articles in the media. ANI Pharmaceuticals' average media sentiment score of 0.52 beat Contineum Therapeutics' score of 0.07 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ANI Pharmaceuticals beats Contineum Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Contineum Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

GH Research is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.73	N/A

In the previous week, Contineum Therapeutics had 5 more articles in the media than GH Research. MarketBeat recorded 6 mentions for Contineum Therapeutics and 1 mentions for GH Research. GH Research's average media sentiment score of 0.67 beat Contineum Therapeutics' score of 0.07 indicating that GH Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Contineum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research presently has a consensus price target of $45.00, suggesting a potential upside of 96.16%. Contineum Therapeutics has a consensus price target of $22.17, suggesting a potential upside of 68.95%. Given GH Research's stronger consensus rating and higher probable upside, analysts plainly believe GH Research is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

GH Research has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

GH Research's return on equity of -20.86% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.86%	-20.12%
Contineum Therapeutics	N/A	-24.73%	-23.51%

56.9% of GH Research shares are owned by institutional investors. 41.6% of GH Research shares are owned by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

GH Research beats Contineum Therapeutics on 11 of the 13 factors compared between the two stocks.

Get Contineum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTNM vs. The Competition

Export

Metric	Contineum Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$488.70M	$12.28B	$7.14B	$13.10B
Dividend Yield	N/A	2.64%	2.53%	16.77%
P/E Ratio	-7.58	794.62	273.77	26.04
Price / Sales	N/A	790.44	622.72	93.41
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	1.88	10.46	10.92	6.30
Net Income	-$59.98M	$2.83B	$3.50B	$361.43M
7 Day Performance	4.46%	-1.56%	-2.07%	-1.67%
1 Month Performance	-25.33%	-5.67%	-6.21%	-4.51%
1 Year Performance	15.59%	-4.72%	7.45%	2.03%

Contineum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTNM Contineum Therapeutics	2.3246 of 5 stars	$13.12 +1.0%	$22.17 +69.0%	+22.0%	$488.70M	N/A	N/A	51	Analyst Forecast
XERS Xeris Biopharma	3.7897 of 5 stars	$9.67 -3.2%	$12.80 +32.4%	+9.3%	$1.76B	$335.41M	N/A	435	News Coverage Insider Trade
CMPS Compass Pathways	2.2849 of 5 stars	$12.67 -2.3%	$23.36 +84.4%	+98.0%	$1.76B	N/A	N/A	156	News Coverage
OCUL Ocular Therapeutix	2.7063 of 5 stars	$7.82 -0.7%	$25.75 +229.5%	-37.1%	$1.72B	$51.95M	N/A	325	News Coverage Analyst Forecast
ANIP ANI Pharmaceuticals	4.4342 of 5 stars	$73.21 +0.8%	$98.00 +33.9%	-19.0%	$1.68B	$883.37M	15.78	970	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTNM) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contineum Therapeutics (CTNM) Competitors

CTNM vs. XERS, CMPS, OCUL, ANIP, and GHRS

How does Contineum Therapeutics compare to Xeris Biopharma?

Summary

How does Contineum Therapeutics compare to Compass Pathways?

Summary

How does Contineum Therapeutics compare to Ocular Therapeutix?

Summary

How does Contineum Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Contineum Therapeutics compare to GH Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Contineum Therapeutics (CTNM) Competitors

CTNM vs. XERS, CMPS, OCUL, ANIP, and GHRS

How does Contineum Therapeutics compare to Xeris Biopharma?

Does the media prefer CTNM or XERS?

Which has higher valuation & earnings, CTNM or XERS?

Which has more volatility and risk, CTNM or XERS?

Do institutionals & insiders hold more shares of CTNM or XERS?

Is CTNM or XERS more profitable?

Do analysts recommend CTNM or XERS?

Summary

How does Contineum Therapeutics compare to Compass Pathways?

Is CMPS or CTNM more profitable?

Does the media refer more to CMPS or CTNM?

Which has more risk & volatility, CMPS or CTNM?

Which has higher earnings & valuation, CMPS or CTNM?

Do insiders and institutionals have more ownership in CMPS or CTNM?

Do analysts rate CMPS or CTNM?

Summary

How does Contineum Therapeutics compare to Ocular Therapeutix?

Which has more risk & volatility, OCUL or CTNM?

Does the media favor OCUL or CTNM?

Do insiders & institutionals believe in OCUL or CTNM?

Is OCUL or CTNM more profitable?

Which has better earnings and valuation, OCUL or CTNM?

Do analysts recommend OCUL or CTNM?

Summary

How does Contineum Therapeutics compare to ANI Pharmaceuticals?

Is ANIP or CTNM more profitable?

Do analysts recommend ANIP or CTNM?

Do institutionals & insiders hold more shares of ANIP or CTNM?

Which has more risk & volatility, ANIP or CTNM?

Which has higher valuation and earnings, ANIP or CTNM?

Does the media favor ANIP or CTNM?

Summary

How does Contineum Therapeutics compare to GH Research?

Which has preferable earnings & valuation, GHRS or CTNM?

Does the media favor GHRS or CTNM?

Do analysts recommend GHRS or CTNM?

Which has more volatility & risk, GHRS or CTNM?

Is GHRS or CTNM more profitable?

Do institutionals and insiders hold more shares of GHRS or CTNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM vs. The Competition

Contineum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools